#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13318	16S	1529	1529	99.74	16S.l6.c17.ctg.1	2031	649.9	0	.	n	.	0	C321T	SNP	321	321	C	481	481	T	734	T,C	374,294	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13318	16S	1529	1529	99.74	16S.l6.c17.ctg.1	2031	649.9	0	.	n	.	0	A337G	SNP	337	337	A	497	497	G	751	G,A	390,293	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13318	16S	1529	1529	99.74	16S.l6.c17.ctg.1	2031	649.9	0	.	n	.	0	T1157C	SNP	1157	1157	T	1317	1317	C	739	C,G,T	618,4,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13318	16S	1529	1529	99.74	16S.l6.c17.ctg.1	2031	649.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1610	1610	T	726	T,C	646,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13318	16S	1529	1529	99.74	16S.l6.c17.ctg.1	2031	649.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1344	1344	C	785	C,T	721,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13318	16S	1529	1529	99.74	16S.l6.c17.ctg.1	2031	649.9	0	HET	.	.	.	C450T	.	450	450	C	610	610	C	791	C,T	589,128	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13318	16S	1529	1529	99.74	16S.l6.c17.ctg.1	2031	649.9	0	HET	.	.	.	T536C,A	.	536	536	T	696	696	T	751	T,C,A	427,266,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24928	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3631	685.0	0	.	n	.	0	C1623T	SNP	1623	1623	C	2036	2036	T	826	T,G,C	710,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24928	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3631	685.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2384	2384	C	822	C,T	727,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24928	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3631	685.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2458	2458	A	824	A	765	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24928	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3631	685.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3010	3010	C	796	C,A	734,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24928	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3631	685.0	0	HET	.	.	.	C2626CGGGGG,CGGGG	.	2626	2626	C	3039	3039	C	818	CGGGGG,CGGGG	621,120	.	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1770	folP	855	855	100.0	folP.l15.c30.ctg.1	1285	135.8	1	SNP	p	R229S	1	.	.	685	687	AGC	901	903	AGC	202;200;201	A;G;C	186;181;181	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4592	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3423	133.9	1	SNP	p	S91F	1	.	.	271	273	TTC	569	571	TTC	158;155;159	T;T;C	145;144;146	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4592	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3423	133.9	1	SNP	p	D95G	1	.	.	283	285	GGC	581	583	GGC	163;162;163	G;G;C	147;144;144	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4592	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3423	133.9	1	SNP	p	G95N	0	.	.	283	285	GGC	581	583	GGC	163;162;163	G;G;C	147;144;144	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1488	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1382	107.4	1	SNP	p	G45D	1	.	.	133	135	GAC	573	575	GAC	193;193;193	G;A,G;C	177;174,2;181	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	820	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	918	89.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4138	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2692	152.1	1	SNP	p	D86N	0	.	.	256	258	GAC	512	514	GAC	159;161;162	G;A;C	152;152;153	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4138	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2692	152.1	1	SNP	p	S87W	0	.	.	259	261	AGT	515	517	AGT	163;165;167	A;G;T	154;153;155	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4138	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2692	152.1	1	SNP	p	S87R	0	.	.	259	261	AGT	515	517	AGT	163;165;167	A;G;T	154;153;155	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4138	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2692	152.1	1	SNP	p	S87I	0	.	.	259	261	AGT	515	517	AGT	163;165;167	A;G;T	154;153;155	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4138	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2692	152.1	1	SNP	p	S88P	0	.	.	262	264	TCC	518	520	TCC	168;171;169	T;C;C	153;154;155	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3946	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2441	160.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1453	1455	GGC	205;205;203	G;G,A;C	189;186,1;183	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1250	1252	GCA	188;187;189	G,A;C,G;A	171,1;173,1;176	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1253	1255	ATC	191;192;195	A;T;C	176;177;180	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1265	1267	GTG	197;196;192	G;T;G	180;178;174	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1265	1267	GTG	197;196;192	G;T;G	180;178;174	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1769	1771	ACC	180;180;179	A;C;C	159;161;162	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1823	1825	GCG	186;187;188	G;C,T;G	166;153,1;162	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1823	1825	GCG	186;187;188	G;C,T;G	166;153,1;162	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1946	1948	GGT	195;195;195	G;G;T	171;170;171	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1955	1957	GGC	194;192;190	G;G;C,T	169;167;164,1	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3782	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2548	148.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1973	1975	CCG	184;184;185	C;C,T;G	122;149,1;135	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	5272	ponA	2397	2397	99.83	ponA.l15.c4.ctg.1	3158	166.5	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1530	1532	ACG	199;197;196	A;C;G	185;186;183	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	5272	ponA	2397	2397	99.83	ponA.l15.c4.ctg.1	3158	166.5	0	.	p	.	0	A471T	NONSYN	1411	1413	GCA	1818	1820	ACA	178;177;176	A;C;A	157;157;158	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	5272	ponA	2397	2397	99.83	ponA.l15.c4.ctg.1	3158	166.5	0	.	p	.	0	T692M	NONSYN	2074	2076	ACG	2481	2483	ATG	200;202;203	A;T;G	166;178;177	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1952	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1580	122.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	451	451	C	161	C	150	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	1548	187.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	645	647	GGA	220;218;218	G;G;A	198;199;195	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	1548	187.5	0	.	p	.	0	.	INDELS	629	630	AA	848	850	TAG	233;231;230	T;A;G	216;214;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	1548	187.5	0	.	p	.	0	.	MULTIPLE	631	633	TAC	852	855	CAAT	233;232;231;225	C;A;A;T	216;215;216;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	1548	187.5	0	.	p	.	0	N212fs	FSHIFT	634	634	A	857	857	T	225	T	215	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	1548	187.5	1	SNP	p	G120K	0	.	.	358	360	GGT	576	578	GGT	233;231;227	G;G;T	213;212;205	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	1548	187.5	1	SNP	p	A121D	0	.	.	361	363	GCC	579	581	GCC	229;228;228	G;C;C	209;208;210	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	1548	187.5	1	SNP	p	A121N	0	.	.	361	363	GCC	579	581	GCC	229;228;228	G;C;C	209;208;210	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11418	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4857	234.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1971	1973	CAT	272;273;272	C;A,T;T	249;249,1;250	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1154	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1081	106.0	1	SNP	p	V57M	1	.	.	169	171	ATG	652	654	ATG	231;232;233	A;T;G	211;210;211	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	11338	tetM	1920	1920	100.0	tetM.l15.c30.ctg.1	2589	437.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
